Genmab to Hold ASH 2016 Data Review Meeting

Media Release

- **Key Opinion Leaders to discuss daratumumab data presented at the 2016 ASH meeting**
- **Meeting to be webcast live and archived on www.genmab.com**

Copenhagen, Denmark; December 1, 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) will hold an ASH 2016 Data Review Meeting on December 5, 2016 at 8:00 PM Pacific Time (5:00 AM CET / 4:00 AM GMT on 6 December). The event will include presentations by key opinion leaders on data from studies of daratumumab presented at the 58th Annual Meeting of the American Society of Hematology (ASH).

The following cancer experts and senior Genmab staff will speak at the event:

Key Opinion Leaders:
- Dr. Meletios-Athanasios Dimopoulos, National and Kapodistrian University of Athens, School of Medicine
- Prof. Philippe Moreau, University Hospital of Nantes
- Dr. Saad Usmani, University of North Carolina at Chapel Hill, Levine Cancer Institute

Genmab:
- Dr. Jan van de Winkel, President and CEO, Genmab
- David Eatwell, Executive Vice President and CFO, Genmab

The Data Review Meeting will take place at the Manchester Grand Hyatt in San Diego, California, Harbor Ballroom A. Those wishing to attend in person should email c.hahner@genmab.com

The event can also be attended via webcast. To view this webcast visit: http://edge.media-server.com/m/p/fatt4nhn. Webcast viewers may submit questions during the Q&A portion of the live webcast via the webcast player. An archive of the webcast will be available on Genmab's website. The webcast will be conducted in English.

This meeting is not an official program of the ASH Annual Meeting.

About Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, non-Hodgkin's lymphoma and solid tumors. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Media Release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or

Genmab to Hold ASH 2016 Data Review Meeting

performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements in relation to actual results, unless required by law.